Trials / Conditions / Ventilator-associated Bacterial Pneumonia

Ventilator-associated Bacterial Pneumonia

12 registered clinical trials studyying Ventilator-associated Bacterial Pneumonia — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Clinical Trial to Assess the Safety and PK of OMN6 in HABP or VABP Caused by Acinetobacter Baumannii Complex NCT06087536	Omnix Medical Ltd	Phase 2
Recruiting	Optimising TREATment for Severe Gram-Negative Bacterial Infections NCT07004049	National University of Singapore	Phase 4
Completed	P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available T NCT05905055	Meiji Seika Pharma Co., Ltd.	Phase 3
Completed	Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With I NCT03894046	Entasis Therapeutics	Phase 3
Completed	Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Participants With Hospital-Acquire NCT03583333	Merck Sharp & Dohme LLC	Phase 3
Withdrawn	A Study of Meropenem-Vaborbactam Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired and Ven NCT03006679	Melinta Therapeutics, Inc.	Phase 3
Completed	Oropharyngeal Aspiration to Reduce Ventilator-Related Pneumonia NCT04107363	Ayşe AKBIYIK	N/A
Completed	Telavancin Observational Use Registry (TOUR) NCT02288234	Cumberland Pharmaceuticals	—
Completed	Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections i NCT02168946	Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)	Phase 3
Completed	Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae NCT02420366	Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)	—
Unknown	The Effect of Ulinastatin on Bronchoalveolar Lavage Fluid of Inflammatory Factors in Patients With Ventilator- NCT01865266	Shanghai Minhang Central Hospital	Phase 2 / Phase 3
Completed	Trial of Colistin Versus Meropenem in Ventilator-associated Pneumonia (VAP) (CR-GNB) NCT01292031	Fundación Pública Andaluza para la gestión de la Investigación en Sevilla	Phase 3